| |
|
|
| |
Prescription Drug Patches to 2015
Products, Indications, Markets and Opportunities
|
Publication: August 2011
Product Code: PSP488R
|
Transdermal drug patches offer the advantages of ease
of use, painlessness, disposability, control of drug
delivery and avoidance of first-pass metabolism by the
liver. Advances in synthetic materials and patch design have
led to patches that are more esthetically acceptable and
that are capable of delivering sustained dosing of active
compounds for several days in a smaller package. Patches
relying on passive transport mechanisms have been limited in
their ability to deliver new classes of drugs, but
formulations employing penetration enhancers, and patch
designs incorporating microporation and energy-assisted
delivery are expanding the range of drugs that can be
effectively delivered transdermally. Growth in demand for
drug patches is being driven by several factors – factors
with strong demographic and population trend underpinnings.
Further improvements to transdermal transport and the
introduction of new patch designs will keep this segment
expanding through 2015.
. |
|
Highlights |
· Analyzes and evaluates
prescription skin patch products
and assesses risks and market potential
· Analyzes patch designs,
technologies and patch development issues
· Provides
assessments of prescription skin patch products in two
dozen key market segments
· Provides market data
and forecasts to 2015
· Profiles patch
manufacturers, their product development
activities and strategies
|
|
Summary of Contents |
Executive Summary
The Transdermal Drug
Delivery Market Dynamics
Drug Patch Market
Structure
Important Patch Drug Therapies
Transdermal Drug Packaging
Demand Drivers
Competitive Landscape
Factors Limiting Growth
Prescription Patch Design & Technology
Patch Architecture
Passive Transdermal Patch
Design
Passive Patch Construction
Active
Transport Patch Technologies
Evolving
Prescription Patch Technologies
Prescription Patch Development Factors
The
Design Cycle
Design Partnerships
Patch Product
Testing
Trials and Submissions
Pharmacokinetics & Dosage Forms
Patch
Manufacturing Dynamics
Patch Manufacturing
Company Profiles
Drugs Currently Delivered in
Approved Transdermal Patches
Buprenoorphine
Clonidine
Diclofenac
Estradiol
Estradiol/Norethrindone
acetate
Fentanyl
Lidocaine
Mecamylamine
Methylphenidate
Nitroglycerin
Norelgestromin
Oxybutynin
Rivastigmine
Rotigotine (EU)
Scopolamine
Selegiline
Testosterone
Drugs in Development for Transdermal Patch
Delivery Systems
Antivirals
CNS
Hormones
Metabolic
Pain Management
Prescription Patch Design & Acceptance Factors
Dosing and Rate Factors
Materials
Compatibility
Clinical Trial Process
Biocompatibility
Market Factors
FDA
Regulations
Rx-to-OTC Switching
New Patch
Technologies
Skin Patch Revenue Models
FDA-Approved Patch Therapies – Analysis and Market
Data
ADHD
Contraception
Cardiovascular/Angina
Depression
Hormone
Replacement Therapy
Hypertension
Motion
Sickness
Neurology
Osteoporosis
Pain
Management
Emerging Patch Therapeutics –
Opportunity and Risk Assessment
Addiction
Neurology
Antiviral
Asthma
Oncology
Diabetes
Neurology
Reproductive Medicine
Sexual Dysfunction
Vaccines
Profiles of
Market Participants
|
|
|
|
|
